RACURA ONCOLOGY LTD

Racura Oncology’s shares stay flat at AUD 1.53 after a steep 24% drop, yet its oncology research and cardio‑protective programs promise new treatment insights.

Racura Oncology’s stock dips 1.9% as it trades below its 200‑day SMA and 52‑week low, spotlighting the company‑specific risk amid a weak Australian market. Explore clinical milestones and regulatory catalysts that could spark a rebound.